Evogene (EVGN) Operating Expenses (2012 - 2026)
Evogene (EVGN) posted Operating Expenses of $3.4 million for Q1 2026, up 3.45% sequentially from $3.2 million in Q4 2025, and down 12.95% YoY from $3.9 million in Q1 2025.
Evogene (EVGN) Operating Expenses (2012 - 2026) Analysis & Trends
Evogene has reported Operating Expenses for 15 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Operating Expenses fell 12.95% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.3 million (down 32.52% YoY) and the FY2025 annual result came in at $13.8 million, down 37.31% from the prior year.
- Operating Expenses climbed to $3.4 million in Q1 2026 per EVGN's latest filing, from $3.2 million in the prior quarter.
- Over five years, Operating Expenses peaked at $8.1 million in Q1 2022 and troughed at $2.9 million in Q3 2025.
- A 5-year average of $5.8 million and a median of $6.6 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses soared 91.47% in 2023, then slumped 56.5% in 2025.
- Over 5 years, Operating Expenses stood at $4.1 million in 2022, then surged by 91.47% to $7.8 million in 2023, then plunged by 44.53% to $4.3 million in 2024, then declined by 25.14% to $3.2 million in 2025, then gained by 3.45% to $3.4 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $3.4 million, $3.2 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 3.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.35 Mn |
| Dec 31, 2025 | 3.24 Mn |
| Sep 30, 2025 | 2.88 Mn |
| Jun 30, 2025 | 3.82 Mn |
| Mar 31, 2025 | 3.85 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Sep 30, 2024 | 6.62 Mn |
| Jun 30, 2024 | 4.90 Mn |
| Mar 31, 2024 | 7.97 Mn |
| Dec 31, 2023 | 7.81 Mn |
| Sep 30, 2023 | 7.44 Mn |
| Jun 30, 2023 | 8.09 Mn |
| Mar 31, 2023 | 7.12 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Sep 30, 2022 | 7.44 Mn |
| Jun 30, 2022 | 8.06 Mn |
| Mar 31, 2022 | 8.13 Mn |
| Dec 31, 2021 | 8.74 Mn |
| Sep 30, 2021 | 8.61 Mn |
| Jun 30, 2021 | 7.45 Mn |